Lipella Pharmaceuticals Inc.
LIPO
$2.52
$0.031.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 116.04% | -41.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 116.04% | -41.06% | |||
| Cost of Revenue | 1.49% | 58.21% | |||
| Gross Profit | 8.03% | -84.02% | |||
| SG&A Expenses | 14.09% | 15.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.53% | 41.45% | |||
| Operating Income | 0.56% | -53.27% | |||
| Income Before Tax | 0.20% | -53.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.20% | -53.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.20% | -53.99% | |||
| EBIT | 0.56% | -53.27% | |||
| EBITDA | 0.56% | -53.42% | |||
| EPS Basic | 7.70% | -30.82% | |||
| Normalized Basic EPS | 7.70% | -30.83% | |||
| EPS Diluted | 7.70% | -30.82% | |||
| Normalized Diluted EPS | 7.70% | -30.83% | |||
| Average Basic Shares Outstanding | 8.12% | 17.71% | |||
| Average Diluted Shares Outstanding | 8.12% | 17.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||